We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unlocking Q2 Potential of Alnylam (ALNY): Exploring Wall Street Estimates for Key Metrics
Read MoreHide Full Article
In its upcoming report, Alnylam Pharmaceuticals (ALNY - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $2.05 per share, reflecting an increase of 540.6% compared to the same period last year. Revenues are forecasted to be $1.32 billion, representing a year-over-year increase of 70.4%.
Over the last 30 days, there has been an upward revision of 2% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
With that in mind, let's delve into the average projections of some Alnylam metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts' assessment points toward 'Revenues- Product revenues, net' reaching $1.21 billion. The estimate points to a change of +80.2% from the year-ago quarter.
Analysts expect 'Revenues- Net revenues from collaborations' to come in at $51.11 million. The estimate points to a change of -16.9% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenues- Royalty revenue' should arrive at $56.25 million. The estimate suggests a change of +40.7% year over year.
The consensus among analysts is that 'Net Product Revenue- Oxlumo' will reach $53.69 million. The estimate points to a change of +14.5% from the year-ago quarter.
The average prediction of analysts places 'Net Product Revenue- Givlaari' at $82.64 million. The estimate suggests a change of +2.2% year over year.
The collective assessment of analysts points to an estimated 'Net Product Revenue- Onpattro' of $24.19 million. The estimate points to a change of -53.7% from the year-ago quarter.
Analysts forecast 'Net Product Revenue- Amvuttra' to reach $1.05 billion. The estimate indicates a year-over-year change of +113.3%.
Shares of Alnylam have demonstrated returns of -5.2% over the past month compared to the Zacks S&P 500 composite's +1.7% change. With a Zacks Rank #3 (Hold), ALNY is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Unlocking Q2 Potential of Alnylam (ALNY): Exploring Wall Street Estimates for Key Metrics
In its upcoming report, Alnylam Pharmaceuticals (ALNY - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $2.05 per share, reflecting an increase of 540.6% compared to the same period last year. Revenues are forecasted to be $1.32 billion, representing a year-over-year increase of 70.4%.
Over the last 30 days, there has been an upward revision of 2% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
With that in mind, let's delve into the average projections of some Alnylam metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts' assessment points toward 'Revenues- Product revenues, net' reaching $1.21 billion. The estimate points to a change of +80.2% from the year-ago quarter.
Analysts expect 'Revenues- Net revenues from collaborations' to come in at $51.11 million. The estimate points to a change of -16.9% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenues- Royalty revenue' should arrive at $56.25 million. The estimate suggests a change of +40.7% year over year.
The consensus among analysts is that 'Net Product Revenue- Oxlumo' will reach $53.69 million. The estimate points to a change of +14.5% from the year-ago quarter.
The average prediction of analysts places 'Net Product Revenue- Givlaari' at $82.64 million. The estimate suggests a change of +2.2% year over year.
The collective assessment of analysts points to an estimated 'Net Product Revenue- Onpattro' of $24.19 million. The estimate points to a change of -53.7% from the year-ago quarter.
Analysts forecast 'Net Product Revenue- Amvuttra' to reach $1.05 billion. The estimate indicates a year-over-year change of +113.3%.
View all Key Company Metrics for Alnylam here>>>Shares of Alnylam have demonstrated returns of -5.2% over the past month compared to the Zacks S&P 500 composite's +1.7% change. With a Zacks Rank #3 (Hold), ALNY is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .